Abemaciclib: First Global Approval
- 251 Downloads
Abemaciclib (Verzenio™) is an orally administered inhibitor of cyclin-dependent kinases 4 and 6 that is being developed by Eli Lilly and Company. Abemaciclib has been approved in the USA for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, in combination with fulvestrant in women with disease progression following endocrine therapy, and as monotherapy in adult patients with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. In addition, abemaciclib is in various stages of development internationally for a variety of cancers. This article summarizes the milestones in the development of abemaciclib leading to its first approval for the treatment of patients with HR-positive, HER2-negative advanced or metastatic breast cancer.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflicts of interest
During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Esther Kim is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.
Additional information about this Adis Drug Review can be found at http://www.medengine.com/Redeem/3BCCF0602F7F3723.
- 1.Adis Insight. Drug profile: abemaciclib. 2017. http://www.adisinsight.springer.com. Accessed 13 Oct 2017.
- 3.Eli Lilly and Company. VERZENIO™ (abemaciclib): US prescribing information. 2017. https://www.fda.gov. Accessed 17 Oct 2017.
- 4.US FDA. FDA approves new treatment for certain advanced or metastatic breast cancers [media release]. 28 Sep 2017. https://www.fda.gov.
- 7.Eli Lilly and Company. FDA grants priority review for potential new indication for Lilly’s Verzenio™ (abemaciclib) as initial treatment of advanced breast cancer [media release]. 12 Oct 2017. https://www.lilly.com.
- 8.Eli Lilly. Lilly and AstraZeneca expand immuno-oncology research collaboration with new combinations [media release]. 22 Oct 2015. https://www.lilly.com/.
- 9.Eli Lilly. Lilly and Merck expand immuno-oncology collaboration adding abemaciclib and KEYTRUDA® combination trial [media release]. 10 Dec 2015. https://www.lilly.com/.
- 12.Hurvitz S, Martin M, Fernandez Abad M, et al. Biological effects of abemaciclib in a phase 2 neoadjuvant study for post-menopausal patients with HR+, HER2-breast cancer [abstract no. S4-06]. Cancer Res. 2017;77(4 Suppl).Google Scholar
- 13.Hurvitz S, Abad MF, Rostorfer R, et al. Interim results from neoMONARCH: a neoadjuvant phase II study of abemaciclib in postmenopausal women with HR +/HER2-breast cancer (BC) [abstract no. LBA13]. Ann Oncol. 2016;27(Suppl 6).Google Scholar
- 14.Goodman A. Abemaciclib plus anastrozole: promising signals reported in phase II study of early breast cancer. 2017. http://www.ascopost.com Accessed 2 Nov 2017.
- 16.AstraZeneca Pharmaceuticals. FASLODEX® (fulvestrant) injection: US prescribing information. 2017. https://www.fda.gov. Accessed 1 Nov 2017.
- 19.Rugo H, Nanda S, Koustenis A. Subgroup analysis by prior treatment and disease burden in MONARCH 1: a phase 2 study of monotherapy abemaciclib, a CDK4 & 6 inhibitor, in patients with HR+/HER2 metastatic breast cancer (MBC) following chemotherapy [abstract no. P6-11-12]. Cancer Res. 2017;77(4 Suppl).Google Scholar
- 21.Tolaney SM, Lin NU, Thornton D, et al. Abemaciclib for the treatment of brain metastases (BM) secondary to hormone receptor positive (HR+), HER2 negative breast cancer [abstract no. 1019]. J Clin Oncol. 2017;35(15 Suppl).Google Scholar
- 22.US National Library of Medicine. Clinicaltrials.gov. 10 Oct 2017. https://clinicaltrials.gov. Accessed 12 Oct 2017.
- 23.Eli Lilly and Company. Lilly reports topline results from phase 3 JUNIPER trial evaluating Verzenio™ (abemaciclib) in KRAS-mutated, advanced non-small cell lung cancer [media release]. 10 Oct 2017. https://www.lilly.com.
- 24.Goldman JW, Shi P, Reck M, et al. Treatment rationale and study design for the JUNIPER study: a randomized phase III study of abemaciclib with best supportive care versus erlotinib with best supportive care in patients with stage IV non-small-cell lung cancer with a detectable KRAS mutation whose disease has progressed after platinum-based chemotherapy. Clin Lung Cancer. 2016;17(1):80–4.CrossRefPubMedGoogle Scholar